drugset
drugset / Trial / NCT03830528

A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects

NCT03830528 ↗

Phase 1 Completed 48 enrolled Kyowa Kirin, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase I study to assess the safety, tolerability and pharmacokinetics of single and multiple doses of KW-6356 in healthy volunteers

Timeline

Start
2019-02-26
Primary completion
2019-10-10
Completion
2019-10-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject SIPAGLADENANT Small molecule 6 mg Oral
Subject SIPAGLADENANT Small molecule 21 mg Oral
Subject SIPAGLADENANT Small molecule 24 mg Oral
Subject SIPAGLADENANT Small molecule 42 mg Oral
Subject SIPAGLADENANT Small molecule 60 mg Oral

Indications

Parkinson disease